Pursuant to provision of Regulations 30 and 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that the 49th Annual General Meeting of ....

Date: 24th August, 2026 Corporate Services Department, BSE Limited, Phiroze Jeejeebhoy Towers, 1st Floor, Dalal Street, Fort, Mumbai - 400001. Scrip Code: 540204 Sub: Notice of the 49th AGM of the Company for the Financial Year 2025-26. Dear Sir/ Madam, Pursuant to provision of Regulations 30 and 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that the 49th Annual General Meeting of the Company will be held on Tuesday, 22nd day of September, 2026 at 04:00 P.M. (IST) through Video Conferencing/ Other Audio Visual Means (“VC/ OAVM”). Please find enclosed the copy of the Notice of 49th AGM for the Financial Year 2025-26 of the Company. The Notice of the 49th AGM is also being uploaded on the website of the Company at www.eikolifesciences.com and on website of our RTA M/s. Bigshare Services Private Limited at www.ivote.bigshareonline.com. In compliance with the aforesaid circulars, the Annual Report along with the Notice of the AGM is being sent only by electronic mode to those shareholders whose e-mail addresses are registered with the Company/ Registrar and Transfer Agent of the Company/Depository Participants. For those shareholders who have not registered their email ids, a letter providing a weblink from where the Notice of the AGM and Annual Report for the financial year 2025-26 can be accessed is being sent. You are requested to kindly take the afore-mentioned on record and oblige. Thanking you, For Eiko Lifesciences Limited Chintan Doshi Company Secretary and Compliance Officer Membership No: A36190 Eiko LifeSciences Limited, CIN: L65993MH1977PLC258134 Registered Address: 604, Centrum, Opp. TMC Office, Near Satkar Grande Hotel, Wagle Estate, Thane MH 400604 Mobile No.: +919082668855; Email id: investor.rela(cid:415)ons@eikolifesciences.com website: www.eikolifesciences.com NOTICE OF THE 49TH ANNUAL GENERAL MEETING NOTICE IS HEREBY GIVEN THAT the 49th (Forty-Ninth) Annual General Meeting (“AGM”) of Members of Eiko LifeSciences Limited (“Company”) will be held on Tuesday, 22nd day of September, 2026 at 04:00 PM (IST) through Video Conference (“VC”)/ Other Audio visuals Means (“OAVM”), for which purpose the Registered Office of the Company situated at 604, Centrum IT Park, S G Barve Road, Near Mulund Check Naka Wagle Estate, Thane West 400604 shall be deemed as the venue for the Meeting and the proceedings of the AGM shall be deemed to be made thereat, to transact the following business: ORDINARY BUSINESS: 1. To receive, consider and adopt the Audited Standalone and Consolidated Financial Statements of the Company for the Financial Year ended 31st March, 2026 together with the Reports of the Board of Directors and Auditors thereon. The members are requested to consider and if thought fit, to pass the following resolution as an Ordinary Resolution: “RESOLVED THAT pursuant to the provisions of Companies Act, 2013, the approval of the Shareholders of the Company be and is hereby accorded to consider and adopt the Audited Standalone and Consolidated Financial Statements of the Company for the Financial Year ended 31st March, 2026 including the Audited Standalone and Consolidated Balance Sheet as of 31st March, 2026 and the Standalone and Consolidated Statement of Profit and Loss and Cash Flow for the year ended on that date and the Reports of the Board and the Auditors along with their annexures thereon.” 2. Re-appointment of Mr. Bhavesh Dhirajlal Tanna (DIN: 03353445) as a “Director”, liable to retire by rotation, who has offered himself for re- appointment. The members are requested to consider and if thought fit, to pass the following resolution as an Ordinary Resolution: “RESOLVED THAT pursuant to the provisions of Section 152 and other applicable provisions of the Companies Act, 2013, the approval of the Shareholders of the Company be and is hereby accorded to the re- appointment of Mr. Bhavesh Dhirajlal Tanna [Director Identification Number (DIN): 03353445] as a “Director”, who shall be liable to retire by rotation.” SPECIAL BUSINESS: 3. Approval for appointment of Mr. Suraj Mahadev Gaikwad (DIN: 11159369) as an Independent Director of the company. The members are requested to consider and if thought fit, to pass the following resolution as a Special Resolution: “RESOLVED THAT pursuant to Sections 149, 150, 152, 161 and other applicable provisions of the Companies Act, 2013 read with Rules framed thereunder, and other applicable regulations of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (including any statutory modification(s) or re-enactment(s) thereof) and the provisions of the Articles of Association of the Company, approval and recommendation of the Nomination & Remuneration Committee and that of the Board, the approval of the Shareholders of the Company be and is hereby accorded to appoint Mr. Suraj Mahadev Gaikwad (DIN: 11159369) as an Independent Director of the Company for a period of 5 (Five) years, with effect from his original date of appointment i.e, 24th August, 2026, who has submitted a declaration that he meets the criteria of independence as provided in Section 149(6) of the Companies Act, 2013 and the Rules made thereunder and Regulation 16(1)(b) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and is eligible for re- appointment, he shall not be liable to retire by rotation of the Company.” 4. Approval of Material Related Party Transactions entered or to be entered with the related parties as per the required laws and regulations. The members are requested to consider and if thought fit, to pass with or without modification, the following resolution as an Ordinary Resolution: “RESOLVED THAT pursuant to the provisions of Section 188 and other applicable provisions, if any, of the companies Act, 2013, (“the Act”) read with the Companies (Meeting of Board and its Powers) Rules, 2014 and Regulation 23 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”), and also pursuant to the consent of the Audit Committee and the Board of Directors, and subject to such other approvals, consents, permissions and sanctions of other authorities as may be necessary, the approval of the Shareholders of the Company be and is hereby accorded to approve all contracts/ arrangements/ agreements/ transactions (including any modifications, alterations, amendments or renewal thereto), with ‘Related Parties’ within the definition of the Companies Act, 2013 and Listing Regulations, as more particularly enumerated in the explanatory statement to the Notice and on such terms and conditions as may be agreed between the Company and such related parties; RESOLVED FURTHER THAT in this regard, the Board (hereinafter referred to as “the Board” which term shall include any Committee thereof) is hereby authorized to negotiate, finalize, vary, amend, renew, and revise the terms and conditions of the transactions and enter into, sign, execute, renew, modify and amend all agreements, documents and letters thereof, from time to time; Page | 4 RESOLVED FURTHER THAT the Board be and is hereby authorized to do all such acts, deeds, matters and things and execute all such deeds, documents, and writings on an ongoing basis, as may be necessary, pro per or expedient for the purpose of giving effect to the above resolution.” For and on behalf of the Board Registered Office For Eiko LifeSciences Limited 604, Centrum IT Park, S G Barve Road, Near Mulund Check Naka Laxmikant Kabra Wagle Estate, Thane West 400 604 Chairman Phone: 022 - 2539 0009 DIN: 00061346 Email: investor.relations@eikolifesciences.com Date: 24th August 2026 Website: www.eikolifesciences.com Place: Thane NOTES: 1. The relevant Explanatory Statement pursuant to Section 102(1) of the Companies Act, 2013 (‘Act’), in respect of the Special Business under [Showing first 8,000 characters — download PDF for full document]